|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Herbst RS, Morgensztern D and Boshoff C:
The biology and management of non-small cell lung cancer. Nature.
553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pignon JP, Tribodet H, Scagliotti GV,
Douillard JY, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell
R, Seymour L, et al: Lung adjuvant cisplatin evaluation: A pooled
analysis by the LACE Collaborative Group. J Clin Oncol.
26:3552–3559. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zarogoulidis K, Zarogoulidis P, Darwiche
K, Boutsikou E, Machairiotis N, Tsakiridis K, Katsikogiannis N,
Kougioumtzi I, Karapantzos I, Huang H and Spyratos D: Treatment of
non-small cell lung cancer (NSCLC). J Thorac Dis. 5 (Suppl
4):S389–S396. 2013.PubMed/NCBI
|
|
5
|
Bunn PA Jr and Kelly K: New combinations
in the treatment of lung cancer: A time for optimism. Chest. 117 (4
Suppl 1):138S–143S. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Spiro SG and Silvestri GA: One hundred
years of lung cancer. Am J Respir Crit Care Med. 172:523–529. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Choi MK and Kim DD: Platinum transporters
and drug resistance. Arch Pharm Res. 29:1067–1073. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Martin LP, Hamilton TC and Schilder RJ:
Platinum resistance: The role of DNA repair pathways. Clin Cancer
Res. 14:1291–1295. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wangpaichitr M, Wu C, You M, Kuo MT, Feun
L, Lampidis T and Savaraj N: Inhibition of mTOR restores cisplatin
sensitivity through down-regulation of growth and anti-apoptotic
proteins. Eur J Pharmacol. 591:124–127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Seve P and Dumontet C: Chemoresistance in
non-small cell lung cancer. Curr Med Chem Anticancer Agents.
5:73–88. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ohmichi M, Hayakawa J, Tasaka K, Kurachi H
and Murata Y: Mechanisms of platinum drug resistance. Trends
Pharmacol Sci. 26:113–116. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu C, Wangpaichitr M, Feun L, Kuo MT,
Robles C, Lampidis T and Savaraj N: Overcoming cisplatin resistance
by mTOR inhibitor in lung cancer. Mol Cancer. 4:252005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hu L, Chen J, Zhang F, Wang J, Pan J, Chen
J and Wang Y: Aberrant long noncoding RNAs expression profiles
affect cisplatin resistance in lung adenocarcinoma. Biomed Res Int.
2017:74981512017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li Y, Melnikov AA, Levenson V, Guerra E,
Simeone P, Alberti S and Deng Y: A seven-gene CpG-island
methylation panel predicts breast cancer progression. BMC cancer.
15:4172015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fukasawa M, Kimura M, Morita S, Matsubara
K, Yamanaka S, Endo C, Sakurada A, Sato M, Kondo T, Horii A, et al:
Microarray analysis of promoter methylation in lung cancers. J Hum
Genet. 51:368–374. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Moutinho C, Martinez-Cardus A, Santos C,
Navarro-Pérez V, Martínez-Balibrea E, Musulen E, Carmona FJ,
Sartore-Bianchi A, Cassingena A, Siena S, et al: Epigenetic
inactivation of the BRCA1 interactor SRBC and resistance to
oxaliplatin in colorectal cancer. J Natl Cancer Inst.
106:djt3222014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee JH, Kang MJ, Han HY, Lee MG, Jeong SI,
Ryu BK, Ha TK, Her NG, Han J, Park SJ, et al: Epigenetic alteration
of PRKCDBP in colorectal cancers and its implication in tumor cell
resistance to TNFα-induced apoptosis. Clin Cancer Res.
17:7551–7562. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yilmaz A, Menevse S, Konac E and Alp E:
The DNA methyl transferase inhibitor, 5′-aza-2-deoxycitidine,
enhances the apoptotic effect of Mevastatin in human leukemia HL-60
cells. Hum Exp Toxicol. 33:414–423. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim JW, Lee CK, Kim HJ, Shim JJ, Jang JY,
Dong SH, Kim BH, Chang YW and Chi SG: Polymorphisms in PRKCDBP, a
transcriptional target of TNF-α, Are associated with inflammatory
bowel disease in Korean. Intest Res. 13:242–249. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim JW, Kim HJ, Lee CK, Shim JJ, Jang JY,
Dong SH, Kim BH, Chang YW and Chi SG: Elevation of PRKCDBP, a novel
transcriptional target of TNF-α, and its downregulation by
infliximab in patients with ulcerative colitis. Dig Dis Sci.
59:2947–2957. 2014. View Article : Google Scholar : PubMed/NCBI
|
